Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024-01 · 22 (1) · 34-42
DOI: 10.1111/ddg.15251 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 05.11.2023. Verfasst von Luca Mastorino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Biological Products, Psoriasis, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Biologics targeting IL‐23 and IL‐17 show efficacy and safety in the treatment of moderate‐to‐severe psoriasis.
Objective
To investigate drug survival in patients with psoriasis treated with biologics. Patients and methods We performed a comparative evaluation of the achievement of PASI 90 and PASI ≤ 3 at 16, 28, and 52 weeks along with a DS (drug survival) analysis with IL‐17 and IL‐23 inhibitors brodalumab, ixekizumab, secukinumab, risankizumab, tildrakizumab, and guselkumab on 1,057 patients.
Results
IL‐17 inhibitors showed a faster achievement of PASI 90 and PASI ≤ 3 with significant superiority over IL‐23 inhibitors at week 16 (p < 0.001; 56% vs. 42% and 70% vs. 59%, respectively). A difference was shown in favor of IL‐23 inhibitors regarding DS (p < 0.001), which was 88% at 24 months vs. 75% for IL‐17 inhibitors. In multivariate analysis, IL‐23 inhibitors (HR 0.54 CI 0.37–0.78, p = 0.001), and male sex (HR 0.57 CI 0.42–0.76, p < 0.001) were all associated with a lower probability of drug interruption. Risankizumab (HR 0.42 CI 0.26‐0.69, p = 0.001), guselkumab (HR 0.49 CI 0.24–0.99, p = 0.046), and male sex (HR 0.57 CI 0.43–0.77, p < 0.001) were associated with a lower probability of drug interruption than secukinumab.
Conclusions
IL‐23 inhibitors showed the best performance on DS. Overall, the most effective class was IL‐17 inhibitors considering the short‐term effectiveness, but long‐term effectiveness is in favor of anti‐IL‐23.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
ORCID-Profile: Luca Mastorino
Zitieren
APA
Mastorino, L., Dapavo, P., Susca, S., Cariti, C., Siliquini, N., Verrone, A., Stroppiana, E., Ortoncelli, M., Quaglino, P., & Ribero, S. (2024). Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(1), 34-42. https://doi.org/10.1111/ddg.15251
Vancouver
Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024;22(1):34-42. doi:10.1111/ddg.15251
BibTeX
@article{Mastorino2024,
author = {Mastorino, Luca and Dapavo, Paolo and Susca, Sara and Cariti, Caterina and Siliquini, Niccolò and Verrone, Anna and Stroppiana, Elena and Ortoncelli, Michela and Quaglino, Pietro and Ribero, Simone},
title = {Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2024},
volume = {22},
number = {1},
pages = {34--42},
doi = {10.1111/ddg.15251}
}
EUVIMED